Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects

After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration. 

Roche_White_Logo

Like many other big pharma companies, Roche Holding AG spent 2023 looking for late-stage assets to meet their short-term needs ahead of a looming patent cliff. With several large deals now signed, the company can return to its usual approach, characterized by an interest in assets throughout the development continuum.

Key Takeaways
  • After focusing on late-stage assets in 2023, Roche is back to a more holistic approach to dealmaking.

“In 2024, we’re going to see a balance between preclinical research technologies as well as preclinical programs that are anywhere...

More from Leadership

More from In Vivo